Triple-negative breast cancer is an aggressive disease with high unmet need. There has been a historical lack of targeted therapies, although the treatment landscape has evolved with the approval…
Triple-negative breast cancer is an aggressive disease with high unmet need. There has been a historical lack of targeted therapies, although the treatment landscape has evolved with the approval…
The gastroesophageal cancer market (including gastric, gastroesophageal junction, and esophageal cancer) is witnessing a substantial change, largely fueled by the entry of immune checkpoint…
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line…
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line…
Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of obesity/overweight comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…
Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…
Janssen’s interleukin (IL)-12/23 inhibitor Stelara, AbbVie’s tumor necrosis factor-alpha (TNF-α) inhibitor Humira, and Novartis’s IL-17A inhibitor Cosentyx lead the U.S. psoriasis biologics…
China has the greatest burden of hepatitis C virus (HCV) in the world. Chronically infected HCV patients are at a high risk of developing cirrhosis, liver cancer, and early death if left untreated…
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel approaches to reimbursement are rapidly gaining importance. To assist developers of gene…
NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…
NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…
Triptans have long been the mainstay of acute treatment of migraine; however, in 2020, three novel oral nontriptan brands—Eli Lilly’s Reyvow, AbbVie / Allergan’s Ubrelvy, and Biohaven’s…